Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.
Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain.
The National Association of Chain Drug Stores submitted a statement urging transparency, collaboration and prioritization in working with pharmacy and other healthcare stakeholders to help protect patient access and fight prescription drug abuse and diversion.
The Food and Drug Administration on Tuesday announced approval for Movantik (naloxegol), a treatment for opioid-induced constipation in adults.
Purdue Pharma on Thursday shared results from several studies evaluating its investigational pain medication Hysingla ER.
Acura Pharmaceuticals last week announced that it has been awarded a $300,000 grant by the National Institute On Drug Abuse of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx abuse deterrent technology.
Pharmaceutical company Iroko announced today that a new version its anti-inflammatory drug Zorvolex had been approved by the Food and Drug Administration.
The Drug Enforcement Administration issued a final rule rescheduling hydrocodone combination products from schedule III to schedule II of the Controlled Substances Act.
One-in-four Americans admits that they have misused prescription drugs, according to a new national survey by FindLaw.com.